Form 4: CONMED Executive Granted Equity Awards

CONMED Corporation's VP GM Advanced Surgical, Matthew Schabacker, received 9,827 Restricted Stock Units and 11,646 stock options under the 2025 Long-Term Incentive Plan.

Summary

• Matthew Schabacker, the VP GM Advanced Surgical at CONMED Corp, was granted equity awards.
• The awards include 9,827 Restricted Stock Units (RSUs) and 11,646 stock options.
• These grants were made on March 2, 2026, under the Company's 2025 Long-Term Incentive Plan.
• Each RSU represents a contingent right to receive one share of common stock and will generally vest over a three-year period, with 33% vesting one year after the grant date, 33% in the second year, and 34% in the third year.
• The stock options have an exercise price of $45.79 and will generally vest in equal amounts over a four-year period, with the first 25% vesting one year after the grant date.

Sentiment

Score: 7

Explanation: StockSavvy.ai views this as a moderately positive, routine transaction, as it aligns executive incentives with shareholder value creation through long-term equity awards.

Positives

• The grant of equity awards aligns management incentives with shareholder interests, encouraging long-term performance.
• The awards are part of a structured long-term incentive plan, indicating a commitment to executive retention and motivation.

Future Outlook

This filing primarily reports an equity grant and does not contain forward-looking statements or guidance beyond the specified vesting schedules of the awarded securities.

Industry Context

StockSavvy.ai notes that equity grants, particularly through long-term incentive plans, are a standard practice across the medical technology and healthcare industry to attract, retain, and motivate key executives. These grants typically align executive interests with long-term company performance, a common strategy among peers like Stryker or Medtronic.

Comparison to Industry Standards

• Equity compensation, including RSUs and stock options, is a standard component of executive compensation packages in the medical device sector, comparable to practices at companies such as Zimmer Biomet or Boston Scientific.
• The vesting schedules (3-year for RSUs, 4-year for options) are typical for long-term incentive plans designed to encourage executive retention and sustained performance.

Corporate Governance

Related Party Transactions

• Grant of equity awards (RSUs and stock options) to Matthew Schabacker, an officer of CONMED Corporation, as part of his compensation package.

Stakeholder Impact

• Shareholders: Potential positive impact through better alignment of executive incentives with long-term company performance and shareholder value creation.
• Employees: May signal stability in executive compensation practices and a commitment to long-term incentive programs.

Next Steps

• RSUs will vest over a three-year period, with the first 33% vesting one year after the grant date (March 2, 2027).
• Stock options will vest in equal amounts over a four-year period, with the first 25% vesting one year after the grant date (March 2, 2027).

Key Dates

Recommendation

This Form 4 filing reports a routine equity grant to an executive as part of a long-term incentive plan. While it aligns management incentives with shareholder interests, it does not present new information that would fundamentally alter the investment thesis for CONMED Corporation, thus a 'hold' recommendation is maintained.

Keywords

CONMED, CNMD, Matthew Schabacker, Restricted Stock Units, RSUs, Stock Options, Equity Grant, Long-Term Incentive Plan, Executive Compensation, Insider Transaction